Search
N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine
go.drugbank.com/drugs/DB14196ApprovedN-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.
Me-4(18F)DG
go.drugbank.com/drugs/DB19207InvestigationalMe-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).
Synonyms: -d-glucopyranoside, methyl 4-deoxy-4-(fluoro-18f)-, -methyl-4-(F-18)-fluoro-4-deoxy-d-glucopyranosideFlutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalIt is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029] … Flutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density.
Phenoxybenzamine
go.drugbank.com/drugs/DB00925ApprovedInvestigationalAn alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Clothiapine
go.drugbank.com/drugs/DB13256ApprovedClothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.
Metiamide
go.drugbank.com/drugs/DB08805ExperimentalMetiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Bromopride
go.drugbank.com/drugs/DB09018InvestigationalBromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.
Categories: Dopamine D2 Receptor AntagonistsArbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.